Friday, 17 Aug 2018

You are here

Oral Anticoagulation Effective Following Hip and Knee Replacement Surgery

Many protocols call for anticoagulation after total hip or total knee arthroplasty to prevent venous thromboembolism (proximal deep-vein thrombosis or pulmonary embolism), and some reports have suggested a role for aspiring or direct oral anticoagulants as preventative therapy.

Patients undergoing total hip or knee arthroplasty were given oral rivaroxaban (Xarelto) 10 mg until postoperative day 5 and then were randomly assigned to continue rivaroxaban (RIX) or switch to aspirin (81 mg daily) for an additional 9 days after total knee arthroplasty (TKA) or for 30 days after total hip arthroplasty (THA). The primary outcome was venous thromboembolism by 90 days. 

They enrolled 3424 patients (1804 THA and 1620 TKA) were enrolled in the trial. There was no difference in the frequency of venous thromboembolism in the ASA patients (0.64%) and RIX patients (0.70%).

There was no significant difference in major bleeding complications with ASA (0.47%) or RIX (0.29%) post-operatively.

These results suggest that extended prophylaxis with either ASA or RIX was equally effective after an initial 5 days course of RIX following THA or TKA, thereby demonstrating effective prevention of venous thromboembolism with oral direct anticoagulation. 

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Managing Comorbidity and Poor Drug Responses

Comorbidity is pervasive and complicates medical care in general. It can be a by-product of aging. It may result from drug therapy or an inciting disease process and may be part of the constellation that defines the primary disorder. A growing body of evidence that suggests that comorbidity has a significant dampening effect on drug responsiveness and, adds to poorer outcomes in patients with inflammatory arthritis.

Opioid Aversion is Augmenting Spinal Steroid Injections

As physicians turn away from opioids, are they resorting to options that may also be unsafe?

The New York Times reports that some physicians are using the anti-inflammatory drug, Depo-Medrol, for intraspinal injections to manage painful spinal and perispinal disorders.

Company Payments to Rheumatologists, Specialists Linked to Increased ACTH Prescriptions

Despite its exorbitant price tag and paucity of supportive clinical evidence, ACTH (corticotropin) sales have increased in the United States. A recent JAMA article examined its use by specialists and found that those who prescribe ACTH (including rheumatologists, nephrologists, neurologists) received corticotropin-related payments from the products sole manufacturer, Mallinckrod.

Veterans Administration Shuns Marijuana as an Option

Cannabis therapy is legal in 30 states in the US, and soon to be legal in Canada and Great Britian, but the US Veterans Administration continues to reject medical marijuana as a therapeutic option - even in states where it is approved.

Predictors of Methotrexate Non-Response

New research from a UK study suggests that nonresponse to oral or subcutaneous MTX was seen in 43% and is predicted by seronegativity, higher disease activity measures and higher anxiety scores.